Amylin heading back to the FDA with Bydureon app

Armed with a new batch of supporting safety data, Amylin says it will resubmit its long-delayed Bydureon--a follow-up, once-weekly version to the blockbuster Byetta--by next week. The FDA stiffed-armed Amylin and its partners Eli Lilly and Alkermes for the second time last fall, saying they wanted some assurance on potential cardiovascular risks. The companies announced recently that a new study failed to find an issue with heart rhythms. Amylin reported that its losses narrowed in the second quarter but the biopharma company's numbers fell short of analysts' estimates. Story

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.